$GNPX News

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

Genprex Highlights New Peer-Reviewed Research In Mice Identifying Important Role For TUSC2 Tumor Suppressor Gene In Maintaining Cellular Processes Associated With Healthy Brain Aging

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex Shares Rise After Collaboration With Roche Diagnostics

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer

Genprex’s Reqorsa combo secures Canadian patent for lung cancer

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer

Genprex to Participate at BIO International Convention 2026

Genprex Receives Nasdaq Noncompliance Notice

Genprex Files For Mixed Shelf Of Up To $250M

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting

Genprex Q1 EPS $(0.64) Up From $(13.00) YoY

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer